Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Harvard Business School
Baxter
Chubb
Boehringer Ingelheim
Daiichi Sankyo
Cipla
McKesson
Fish and Richardson

Generated: January 22, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022395

« Back to Dashboard

NDA 022395 describes QUTENZA, which is a drug marketed by Averitas and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the QUTENZA profile page.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the capsaicin profile page.
Summary for 022395
Tradename:QUTENZA
Applicant:Averitas
Ingredient:capsaicin
Patents:1
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022395
Generic Entry Date for 022395*:
Constraining patent/regulatory exclusivity:
Dosage:
PATCH;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Medical Subject Heading (MeSH) Categories for 022395
Suppliers and Packaging for NDA: 022395
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
QUTENZA capsaicin PATCH;TOPICAL 022395 NDA Acorda Therapeutics, Inc. 10144-928 10144-928-01 1 KIT in 1 CARTON (10144-928-01) * 50 g in 1 TUBE * 1 PATCH in 1 POUCH (10144-920-00) > 280 cm2 in 1 PATCH
QUTENZA capsaicin PATCH;TOPICAL 022395 NDA Acorda Therapeutics, Inc. 10144-929 10144-929-01 1 KIT in 1 CARTON (10144-929-01) * 50 g in 1 TUBE * 1 PATCH in 1 POUCH > 280 cm2 in 1 PATCH

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:PATCH;TOPICALStrength8%
Approval Date:Nov 16, 2009TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 4, 2021Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Julphar
Covington
Express Scripts
McKesson
Citi
Argus Health
AstraZeneca
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.